# SPINAL CORD INJURY STANDARD OF CARE ACT
## International Legislative Template

*Jurisdiction-neutral draft for adoption, adaptation, or direct introduction*  
*Released under GPL-3.0 — copy it, translate it, table it*  
*Part of the Apex Arc SCI Package*

---

**INSTRUCTIONS FOR USE:**  
Replace bracketed terms with jurisdiction-appropriate equivalents.  
`[JURISDICTION]` — country, state, province, or territory  
`[LEGISLATIVE BODY]` — parliament, congress, assembly, diet, bundestag, etc.  
`[HEALTH MINISTRY]` — relevant ministry or department  
`[NATIONAL HEALTH PROGRAM]` — NHS, Medicare, RAMQ, OHIP, Seguridad Social, etc.  
`[CURRENCY]` — local currency and approximate equivalent figures  

---

## PREAMBLE

The [LEGISLATIVE BODY] of [JURISDICTION] finds:

**1.** Traumatic spinal cord injury (SCI) is a permanent, life-altering condition affecting people of all ages, with incidence concentrated in the 16-to-30 age range. The majority of those injured will live with SCI for decades.

**2.** The injury severs the communication pathway between the brain's motor commands and the muscles below the lesion. In most cases, the brain retains the capacity to generate commands and the muscles retain the capacity to respond. The injury is, in engineering terms, a wire problem — and wire problems have engineering solutions.

**3.** Since 2018, peer-reviewed clinical research has demonstrated that electrical stimulation of the spinal cord enables voluntary movement in patients with complete or near-complete SCI previously considered permanent. This is established fact, not hypothesis.

**4.** The gap between what clinical research has demonstrated and what patients in [JURISDICTION] currently receive constitutes a preventable harm occurring at scale, every day.

**5.** The technology required to close this gap is available, manufacturable, and in many cases already approved for clinical use in at least one jurisdiction. The barrier is not scientific. It is systemic.

**6.** It is the obligation of [JURISDICTION] to remove that barrier.

---

## PART I — MINIMUM STANDARD OF ASSESSMENT

### Article 1 — Neurological Evaluation

**1.1** Any clinician funded by [NATIONAL HEALTH PROGRAM] or operating under license in [JURISDICTION] who treats a patient with traumatic SCI shall complete, within 90 days of first contact or within 90 days of this Act entering into force for existing patients, a full neurological assessment including:

   (a) Classification per the International Standards for Neurological Classification of SCI (ISNCSCI/ASIA)  
   (b) Electromyography of all clinically relevant muscle groups, bilateral  
   (c) Somatosensory evoked potentials across the injury level  
   (d) Motor evoked potentials via transcranial magnetic stimulation to bilateral limb targets  
   (e) MRI of the relevant spinal segments documenting lesion morphology, cord signal change, and any surgically addressable pathology

**1.2** The assessment shall be repeated:

   (a) Following any intervention that may alter neurological status  
   (b) Following any reported change in function, whether improvement or regression  
   (c) Not less than every three years for patients with chronic SCI

**1.3** Failure to complete any element shall be documented with specific clinical justification. Duration of injury, patient age, and absence of recent functional change are not acceptable justifications.

---

### Article 2 — Functional Independence Assessment

**2.1** Within 60 days of neurological assessment, the treating team shall document an evaluation of the patient's access to and eligibility for:

   (a) Powered mobility appropriate to current upper extremity function  
   (b) Alternative drive controls (head array, chin control, eye gaze, breath control) if hand control is insufficient  
   (c) Assistive feeding technology, including mobile arm supports, adaptive utensils, and robotic feeding devices  
   (d) Augmentative communication and environmental control systems  
   (e) Smart home integration for lighting, temperature, door, and appliance control  
   (f) Transfer and positioning equipment appropriate to the patient's attendant care situation

**2.2** The evaluation shall be updated whenever the patient's functional status changes.

---

### Article 3 — Neurostimulation Referral

**3.1** Any patient with traumatic SCI who meets all of the following criteria:

   (a) Injury of twelve months or longer duration  
   (b) Has not achieved functional ambulation or functional upper extremity independence  
   (c) Has not received formal evaluation for neurostimulation candidacy

shall be referred for neurostimulation evaluation within 180 days of this Act entering into force, or within 180 days of meeting the above criteria.

**3.2** Referral shall be to a clinician or centre with documented experience in spinal cord stimulation. Where no such centre exists in [JURISDICTION], referral to an international centre shall be facilitated and costs addressed under Article 7.

**3.3** The outcome of the referral, and any barriers encountered, shall be documented.

---

## PART II — COVERAGE AND REIMBURSEMENT

### Article 4 — Mandatory Coverage

**4.1** [NATIONAL HEALTH PROGRAM], and any private insurer operating under licence in [JURISDICTION], shall provide coverage for:

   (a) **Epidural spinal cord stimulation** — implantation, programming, and ongoing management  
   (b) **Transcutaneous spinal cord stimulation** — device provision and clinical support for non-surgical candidates  
   (c) **Focused ultrasound neuromodulation** — when prescribed for SCI motor rehabilitation or pain management  
   (d) **Functional electrical stimulation systems** — FES cycling for lower extremity injury; FES upper extremity systems for cervical injury with residual proximal function  
   (e) **Wearable neuromuscular stimulation garments** — when prescribed for muscle maintenance and neuromuscular junction preservation  
   (f) **Robotic feeding assistance** — for patients who cannot self-feed due to SCI  
   (g) **Powered transfer assist devices** — when transfers require human physical assistance more than twice daily  
   (h) **Smart home control systems** — when the patient lacks sufficient upper extremity function for standard controls

**4.2** Coverage for any item in Article 4.1 shall not be conditioned on the patient first failing treatments that were not themselves offered under this Act.

**4.3** Where the ten-year cost of an assistive device is less than the ten-year cost of human attendant care providing equivalent function, coverage for the device shall be presumed appropriate.

---

### Article 5 — Appeals

**5.1** Any denial of coverage under Article 4 shall:

   (a) Be issued in writing with specific clinical and evidentiary basis  
   (b) Be reviewed by a clinician with documented SCI expertise  
   (c) Be decided within 72 hours for urgent requests and 21 days for standard requests  
   (d) Be subject to independent external review upon patient request at no cost to the patient

**5.2** Systemic denial patterns — denial of a class of device across multiple patients — shall be subject to review by [HEALTH MINISTRY] and reported in the annual registry under Article 8.

---

## PART III — RESEARCH AND TRANSPARENCY

### Article 6 — Research Priorities

**6.1** [HEALTH MINISTRY] shall designate SCI as a national research priority with specific mandates for:

   (a) Translational research closing the gap between research centre outcomes and home deployment  
   (b) Long-term outcomes in patients with chronic injury (ten or more years post-injury), addressing the clinical assumption — unsupported by evidence — that such patients are not candidates for functional recovery  
   (c) Biocompatibility and efficacy of next-generation neural interface materials including graphene-based electrode arrays and conformable polymer substrates

---

### Article 7 — Equity of Access

**7.1** SCI incidence and outcomes are not uniform across populations. [HEALTH MINISTRY] shall report annually on SCI outcomes stratified by:

   (a) Geographic region  
   (b) Socioeconomic status  
   (c) Ethnicity  
   (d) Age at injury  
   (e) Time from injury to first neurostimulation evaluation

**7.2** Where access to required care is not available within [JURISDICTION], [NATIONAL HEALTH PROGRAM] shall cover the cost of access to the nearest available facility in another jurisdiction.

---

### Article 8 — Public Registry

**8.1** [HEALTH MINISTRY] shall establish and maintain a public registry containing:

   (a) All neurostimulation and assistive devices with regulatory clearance in [JURISDICTION] for SCI  
   (b) All clinical trials currently enrolling SCI patients in [JURISDICTION] or accessible to residents  
   (c) All certified SCI rehabilitation centres in [JURISDICTION]  
   (d) Aggregate coverage denial data by device category  
   (e) Annual functional outcome data for the SCI population

**8.2** The registry shall be publicly accessible, free of charge, in plain language and in accessible formats.

---

## PART IV — RECOGNITION OF SPECIFIC POPULATIONS

### Article 9 — Patients Harmed by Policy Gaps

**9.1** [LEGISLATIVE BODY] recognizes that in jurisdictions where domestic stem cell and regenerative medicine research was restricted or underfunded during the period 2001–2009, patients with SCI who were in active intervention windows sought experimental treatments abroad, in some cases experiencing adverse neurological outcomes including functional regression that may not have occurred had domestically regulated alternatives been available.

**9.2** [HEALTH MINISTRY] shall:

   (a) Identify, to the extent possible, patients in [JURISDICTION] who underwent experimental SCI procedures abroad during the period 2001–2009  
   (b) Provide comprehensive neurological evaluation to those patients at no cost  
   (c) Ensure those patients receive priority access to all programmes established under this Act  
   (d) Document the functional outcomes of that population and include them in the research registry

**9.3** This Article does not assign fault or create liability. It assigns obligation. Policy has consequences. Consequences fall on people. People deserve remedy.

---

## PART V — ENFORCEMENT

### Article 10 — Provider Accountability

**10.1** A provider who fails to meet the assessment or documentation requirements of Part I, upon confirmation by [HEALTH MINISTRY]:

   (a) First finding: written notice and mandatory corrective action plan within 60 days  
   (b) Second finding within 24 months: suspension of [NATIONAL HEALTH PROGRAM] billing for SCI-related services pending completion of corrective action  
   (c) Third finding within 36 months: referral to the relevant professional regulatory body for conduct review

---

### Article 11 — Insurer Accountability

**11.1** An insurer that denies coverage required under Part II without meeting the appeals requirements of Article 5 shall be subject to a civil penalty of not less than [CURRENCY equivalent of USD $10,000] per denial, with each patient denial constituting a separate violation.

**11.2** An insurer that demonstrates a pattern of improper denial — defined as denial of a covered item class at a rate more than two standard deviations above the mean for comparable items — shall be subject to mandatory audit and corrective action under [HEALTH MINISTRY] supervision.

---

## PART VI — DEFINITIONS

**"Chronic SCI"** — traumatic spinal cord injury of twelve months or more duration.

**"Functional independence"** — the capacity to perform activities of daily living, including feeding, hygiene, mobility, and communication, without requiring human physical assistance.

**"Neurostimulation"** — application of electrical, magnetic, or acoustic energy to the nervous system for the purpose of modulating neural activity, encompassing epidural spinal cord stimulation, transcutaneous spinal cord stimulation, transcranial magnetic stimulation, and focused ultrasound neuromodulation.

**"Standard of care"** — the diagnostic and therapeutic interventions that a reasonably competent clinician with training in SCI medicine would provide to a patient with a given clinical profile, based on the best available evidence at the time of treatment.

**"Assistive technology"** — any device, system, or item used to maintain, increase, or improve the functional capabilities of a person with SCI.

---

## PART VII — ENTRY INTO FORCE AND REVIEW

**Article 12** — This Act enters into force [90/180] days after royal assent / presidential signature / legislative passage.

**Article 13** — [HEALTH MINISTRY] shall review this Act and report to [LEGISLATIVE BODY] on implementation progress not later than two years after entry into force, and every three years thereafter.

**Article 14** — Nothing in this Act limits rights available to patients under existing law.

---

*Released under GPL-3.0.*
*This document is public prior art. It may be copied, translated, introduced, tabled, debated, amended, or passed without permission or attribution, though attribution is welcome.*  
*Part of the Apex Arc SCI Package.*